Takayuki Kondo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Takayuki Kondo has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Chihiro Fujii
Department of Neurology, Kansai Medical University Medical Center, Osaka, Japan
6 shared publicationsRyosuke Takahashi
Kyoto University Research Administration Center, Kyoto, Japan
6 shared publicationsMio Hamatani
Department of Neurology, Kyoto University Graduate School of Medicine, Kyoto, Japan
5 shared publicationsShinji Ashida
Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan
5 shared publicationsHirofumi Ochi
Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine, Ehime, Japan
4 shared publicationsKazuyuki Kawamura
Department of Neurology, National Hospital Organization Minami Kyoto Hospital, Kyoto, Japan
4 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7) , 438
Beyond dissemination criteria: lesion-based longitudinal MRI of atypical demyelinating lesions at the boundary of multiple sclerosis
Background: Revisions of the McDonald diagnostic criteria have improved the sensitivity of multiple sclerosis (MS) diagnosis by incorporating MRI-based dissemination in space and time. However, some inflammatory demyelinating lesions fulfill dissemination criteria while showing radiological features atypical for MS, even in the absence of anti-AQP4 and anti-MOG antibodies. The long-term radiological course of these atypical idiopathic inflammatory demyelinating lesions (AIIDLs) remains unclear. Methods: We retrospectively analyzed 39 Japanese patients with AIIDLs, classified into multiple spotty lesions (MSLs), disseminated encephalomyelitis-like lesions (DEMLs), leukoencephalopathy-like lesions (LELs), and tumefactive lesions (TLs), and compared them with 97 patients with radiologically typical MS. Longitudinal MRI analyses evaluated lesion morphology, distribution, volume, and central vein sign (CVS) positivity, together with clinical outcomes and treatment responses. Results: Over a mean follow-up of 11 years, 38 of 39 AIIDL cases (97.4%) retained radiologically atypical features despite clinical relapses and fulfillment of dissemination criteria. MSLs and TLs lacked canonical MS features, such as periventricular lesions and T1 hypointense black holes. Only one case with LELs evolved into typical MS. CVS positivity exceeding 40% was observed in two MSLs cases but lesions remained atypical in distribution. Lesion volumes differed significantly among subgroups, with smaller volumes in MSLs and larger volumes in LELs compared with typical MS. Corticosteroids, immunosuppressants, and B cell depletion therapies appeared to be associated with clinical stabilization in several AIIDL subtypes, whereas conventional MS disease-modifying therapies were less consistently effective. Conclusions: In this cohort, most AIIDLs retained radiologically atypical brain MRI features over long-term follow-up despite recurrent inflammatory demyelinating events. These findings suggest that dissemination-based criteria alone may not fully capture the radiological heterogeneity of AQP4-IgG- and MOG-IgG-negative demyelinating disorders. Longitudinal lesion-based MRI phenotyping may provide complementary information for diagnostic reassessment although external validation and integration with optic nerve, spinal cord, and biological markers are required.
- 1 July 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7) , 438
Open AccessBeyond dissemination criteria: lesion-based longitudinal MRI of atypical demyelinating lesions at the boundary of multiple sclerosis
Background: Revisions of the McDonald diagnostic criteria have improved the sensitivity of multiple sclerosis (MS) diagnosis by incorporating MRI-based dissemination in space and time. However, some inflammatory demyelinating lesions fulfill dissemination criteria while showing radiological features atypical for MS, even in the absence of anti-AQP4 and anti-MOG antibodies. The long-term radiological course of these atypical idiopathic inflammatory demyelinating lesions (AIIDLs) remains unclear. Methods: We retrospectively analyzed 39 Japanese patients with AIIDLs, classified into multiple spotty lesions (MSLs), disseminated encephalomyelitis-like lesions (DEMLs), leukoencephalopathy-like lesions (LELs), and tumefactive lesions (TLs), and compared them with 97 patients with radiologically typical MS. Longitudinal MRI analyses evaluated lesion morphology, distribution, volume, and central vein sign (CVS) positivity, together with clinical outcomes and treatment responses. Results: Over a mean follow-up of 11 years, 38 of 39 AIIDL cases (97.4%) retained radiologically atypical features despite clinical relapses and fulfillment of dissemination criteria. MSLs and TLs lacked canonical MS features, such as periventricular lesions and T1 hypointense black holes. Only one case with LELs evolved into typical MS. CVS positivity exceeding 40% was observed in two MSLs cases but lesions remained atypical in distribution. Lesion volumes differed significantly among subgroups, with smaller volumes in MSLs and larger volumes in LELs compared with typical MS. Corticosteroids, immunosuppressants, and B cell depletion therapies appeared to be associated with clinical stabilization in several AIIDL subtypes, whereas conventional MS disease-modifying therapies were less consistently effective. Conclusions: In this cohort, most AIIDLs retained radiologically atypical brain MRI features over long-term follow-up despite recurrent inflammatory demyelinating events. These findings suggest that dissemination-based criteria alone may not fully capture the radiological heterogeneity of AQP4-IgG- and MOG-IgG-negative demyelinating disorders. Longitudinal lesion-based MRI phenotyping may provide complementary information for diagnostic reassessment although external validation and integration with optic nerve, spinal cord, and biological markers are required.
- Open Access
- 30 January 2023
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (9) , 1950-1951
Immunological role of sulfatide in the pathogenesis of multiple sclerosis
An abstract is unavailable. This article is available as a PDF only.
- 30 January 2023
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 18 (9) , 1950-1951
Open AccessImmunological role of sulfatide in the pathogenesis of multiple sclerosis
An abstract is unavailable. This article is available as a PDF only.
- 11 June 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (9) , 5276-5283
T cells from MS Patients with High Disease Severity Are Insensitive to an Immune-Suppressive Effect of Sulfatide
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Its early phase is characterized by a relapse-remitting disease course, followed by disability progression in the later stage. While chronic inflammation accompanied with degeneration is well-established as the key pathological feature, the pathogenesis of MS, particularly progressive MS, remains elusive. Sulfatide is a major glycolipid component of myelin, and previous studies in experimental autoimmune encephalomyelitis mouse models have demonstrated it to have immune-protective functions. Notably, sulfatide concentration is increased in the serum and cerebrospinal fluid of patients with MS, particularly those in a progressive disease course. Here, we show that the myelin-glycolipid sulfatide displays an ability to suppress the proliferation of polyclonally activated human T cells. Importantly, this suppressive effect was impaired in T cells obtained from MS patients having higher disability status. Therefore, it is plausible that progression of MS is associated with an escape from the immune-regulatory effect of sulfatide. Our study suggests that, although the precise mechanisms remain unrevealed, an escape of T cells from immunosuppression by sulfatide is associated with disease progression in the advanced stage. Further studies will provide novel insights into the pathogenesis of MS, particularly regarding disease progression, and help develop novel treatment strategies for this challenging disease.
- 11 June 2022
- Published by Springer Nature in Molecular Neurobiology
- Vol. 59 (9) , 5276-5283
T cells from MS Patients with High Disease Severity Are Insensitive to an Immune-Suppressive Effect of Sulfatide
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). Its early phase is characterized by a relapse-remitting disease course, followed by disability progression in the later stage. While chronic inflammation accompanied with degeneration is well-established as the key pathological feature, the pathogenesis of MS, particularly progressive MS, remains elusive. Sulfatide is a major glycolipid component of myelin, and previous studies in experimental autoimmune encephalomyelitis mouse models have demonstrated it to have immune-protective functions. Notably, sulfatide concentration is increased in the serum and cerebrospinal fluid of patients with MS, particularly those in a progressive disease course. Here, we show that the myelin-glycolipid sulfatide displays an ability to suppress the proliferation of polyclonally activated human T cells. Importantly, this suppressive effect was impaired in T cells obtained from MS patients having higher disability status. Therefore, it is plausible that progression of MS is associated with an escape from the immune-regulatory effect of sulfatide. Our study suggests that, although the precise mechanisms remain unrevealed, an escape of T cells from immunosuppression by sulfatide is associated with disease progression in the advanced stage. Further studies will provide novel insights into the pathogenesis of MS, particularly regarding disease progression, and help develop novel treatment strategies for this challenging disease.
- Open Access
- 13 October 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Radiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan
Background: Multiple sclerosis (MS) is a relapsing, inflammatory, and demyelinating disease of central nervous system showing marked clinical heterogeneity. Many factors might influence the choice of relapse prevention drug, and treatment response varies among patients. Despite the enlargement of disease-modifying drugs for MS (MS-DMDs), some patients have been treated with corticosteroid and/or immunosuppressant (CS/IS).Objective: To clarify the radiological and laboratory features of MS treated with CS/IS for relapse prevention.Methods: Clinical records including radiological and laboratory findings, and drugs used for relapse prevention were reviewed retrospectively.Results: Out of 92 consecutive MS patients, 25 (27%) were treated with CS/IS. The followings were observed less frequently in patients treated with CS/IS than in those with MS-DMDs: three or more periventricular lesions, ovoid lesions, subcortical lesions, typical contrast-enhancing lesions, negative for serum autoantibodies, and positive for oligoclonal bands in the cerebrospinal fluid. Multiple logistic regression analysis revealed that the absence of typical contrast-enhancing lesions and positivity for serum autoantibodies were independent factors associated with CS/IS prescription (odds ratio 25.027 and 14.537, respectively).Conclusion: In this cohort of Japanese patients clinically diagnosed with MS, radiological and serological findings atypical of MS were observed more frequently in patients treated with CS/IS than in those with MS-DMDs as a part of MS therapy. The absence of contrast-enhancing lesions typical of MS and positivity for serum autoantibodies were independent factors strongly associated with CS/IS use.
- 13 October 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Open AccessRadiological and Laboratory Features of Multiple Sclerosis Patients With Immunosuppressive Therapy: A Multicenter Retrospective Study in Japan
Background: Multiple sclerosis (MS) is a relapsing, inflammatory, and demyelinating disease of central nervous system showing marked clinical heterogeneity. Many factors might influence the choice of relapse prevention drug, and treatment response varies among patients. Despite the enlargement of disease-modifying drugs for MS (MS-DMDs), some patients have been treated with corticosteroid and/or immunosuppressant (CS/IS).Objective: To clarify the radiological and laboratory features of MS treated with CS/IS for relapse prevention.Methods: Clinical records including radiological and laboratory findings, and drugs used for relapse prevention were reviewed retrospectively.Results: Out of 92 consecutive MS patients, 25 (27%) were treated with CS/IS. The followings were observed less frequently in patients treated with CS/IS than in those with MS-DMDs: three or more periventricular lesions, ovoid lesions, subcortical lesions, typical contrast-enhancing lesions, negative for serum autoantibodies, and positive for oligoclonal bands in the cerebrospinal fluid. Multiple logistic regression analysis revealed that the absence of typical contrast-enhancing lesions and positivity for serum autoantibodies were independent factors associated with CS/IS prescription (odds ratio 25.027 and 14.537, respectively).Conclusion: In this cohort of Japanese patients clinically diagnosed with MS, radiological and serological findings atypical of MS were observed more frequently in patients treated with CS/IS than in those with MS-DMDs as a part of MS therapy. The absence of contrast-enhancing lesions typical of MS and positivity for serum autoantibodies were independent factors strongly associated with CS/IS use.
- Open Access
- 4 March 2021
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 8 (2)
Immune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity
Objective To clarify functional alterations of follicular helper T cells (Tfh) in myasthenia gravis (MG) because Tfh play important roles in helping B cells generate antibody-producing cells. Methods A total of 24 immunotherapy-naive patients with anti–acetylcholine receptor (AchR) antibody–positive MG and 18 age-matched healthy subjects (HS) were enrolled. Samples from 6 patients were available for posttreatment analysis. Subsets of circulating Tfh (cTfh) and B cells were identified by flow cytometry analysis of surface molecules. Cytokine production by isolated cTfh subsets from 5 patients with MG and 5 HS was measured in vitro. Analysis was performed to examine the correlation between the frequency of cTfh subsets and that of plasmablasts and between cTfh subsets and the quantitative MG score. Results cTfh increased with elevated expression of inducible T-cell costimulator (ICOS) in patients with MG. cTfh shifted to Th2 and Th17 over Th1 in MG. ICOShighcTfh produced significantly higher levels of interleukin (IL)-21, IL-4, and IL-17A than ICOSlow cTfh only in patients with MG. The frequency of cTfh within CD4 T cells was more closely associated with disease severity than the serum anti-AchR antibody titer and frequency of plasmablasts within B cells. Abnormalities of cTfh were improved after immunotherapy in parallel with clinical improvement. Conclusions Alternation of cTfh is a key feature in the development of MG and may become a biomarker for disease severity and therapeutic efficacy. Classification of Evidence This study provides Class II evidence that the level of cTfh is associated with disease severity in patients with MG.
- 4 March 2021
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 8 (2)
Open AccessImmune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity
Objective To clarify functional alterations of follicular helper T cells (Tfh) in myasthenia gravis (MG) because Tfh play important roles in helping B cells generate antibody-producing cells. Methods A total of 24 immunotherapy-naive patients with anti–acetylcholine receptor (AchR) antibody–positive MG and 18 age-matched healthy subjects (HS) were enrolled. Samples from 6 patients were available for posttreatment analysis. Subsets of circulating Tfh (cTfh) and B cells were identified by flow cytometry analysis of surface molecules. Cytokine production by isolated cTfh subsets from 5 patients with MG and 5 HS was measured in vitro. Analysis was performed to examine the correlation between the frequency of cTfh subsets and that of plasmablasts and between cTfh subsets and the quantitative MG score. Results cTfh increased with elevated expression of inducible T-cell costimulator (ICOS) in patients with MG. cTfh shifted to Th2 and Th17 over Th1 in MG. ICOShighcTfh produced significantly higher levels of interleukin (IL)-21, IL-4, and IL-17A than ICOSlow cTfh only in patients with MG. The frequency of cTfh within CD4 T cells was more closely associated with disease severity than the serum anti-AchR antibody titer and frequency of plasmablasts within B cells. Abnormalities of cTfh were improved after immunotherapy in parallel with clinical improvement. Conclusions Alternation of cTfh is a key feature in the development of MG and may become a biomarker for disease severity and therapeutic efficacy. Classification of Evidence This study provides Class II evidence that the level of cTfh is associated with disease severity in patients with MG.
- Open Access
- 1 July 2020
- Published by Elsevier in Neurobiology of Disease
- Vol. 140, 104867
Altered features of monocytes in adult onset leukoencephalopathy with axonal spheroids and pigmented glia: A clue to the pathomechanism of microglial dyshomeostasis
- 1 July 2020
- Published by Elsevier in Neurobiology of Disease
- Vol. 140, 104867
Open AccessAltered features of monocytes in adult onset leukoencephalopathy with axonal spheroids and pigmented glia: A clue to the pathomechanism of microglial dyshomeostasis
- Open Access
- 7 January 2019
- Published by Springer Nature in BMC Neurology
- Vol. 19 (1) , 5
A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries
Delayed-release dimethyl fumarate (DMF) has demonstrated efficacy and a favorable benefit-risk profile in phase 2 and 3 studies that enrolled predominantly white patients with relapsing-remitting multiple sclerosis (RRMS). In this study (APEX, Part I), we evaluated the efficacy/safety outcomes of DMF in a predominantly East Asian population of patients with RRMS. In this 24-week, randomized, double-blind, placebo-controlled phase 3 study, 225 patients, 142 of which were East Asian (63.4%), were enrolled: Japan (n = 114), South Korea (n = 20), Taiwan (n = 8), the Czech Republic (n = 42), and Poland (n = 40). Key exclusion criteria included diagnosis of neuromyelitis optica spectrum disorder. Stratified by country, patients were randomized 1:1 to receive DMF 240 mg twice daily or placebo. Clinical assessments, including neurological examination and EDSS scoring, were conducted at baseline and at weeks 12 and 24. A total of 213 patients (95.1%) completed the study. From weeks 12 – 24, the total number of new gadolinium-enhancing (Gd+) lesions was reduced by 84% (p < 0.0001) in DMF compared with placebo. For the secondary endpoint, from baseline to week 24, the total number of new Gd+ lesions was reduced by 75% and the mean number of new/newly enlarging T2 hyperintense lesions was reduced by 63% (both p < 0.0001). Flushing and flushing-related symptoms, and gastrointestinal events were adverse events related to DMF treatment. Efficacy and safety results in the Japanese subgroup and the East Asian subgroup (which included patients from Japan, Taiwan, and South Korea) were consistent with the overall study population. The strong efficacy and favorable benefit-risk profile of DMF extends to Japanese, and more broadly, East Asian patients with RRMS. This trial is registered on ClinicalTrials.gov (identifier: NCT01838668 ), April 20, 2013 (retrospectively registered). The registration can be found at the following URL: https://clinicaltrials.gov/ct2/show/NCT01838668
- 7 January 2019
- Published by Springer Nature in BMC Neurology
- Vol. 19 (1) , 5
Open AccessA randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries
Delayed-release dimethyl fumarate (DMF) has demonstrated efficacy and a favorable benefit-risk profile in phase 2 and 3 studies that enrolled predominantly white patients with relapsing-remitting multiple sclerosis (RRMS). In this study (APEX, Part I), we evaluated the efficacy/safety outcomes of DMF in a predominantly East Asian population of patients with RRMS. In this 24-week, randomized, double-blind, placebo-controlled phase 3 study, 225 patients, 142 of which were East Asian (63.4%), were enrolled: Japan (n = 114), South Korea (n = 20), Taiwan (n = 8), the Czech Republic (n = 42), and Poland (n = 40). Key exclusion criteria included diagnosis of neuromyelitis optica spectrum disorder. Stratified by country, patients were randomized 1:1 to receive DMF 240 mg twice daily or placebo. Clinical assessments, including neurological examination and EDSS scoring, were conducted at baseline and at weeks 12 and 24. A total of 213 patients (95.1%) completed the study. From weeks 12 – 24, the total number of new gadolinium-enhancing (Gd+) lesions was reduced by 84% (p < 0.0001) in DMF compared with placebo. For the secondary endpoint, from baseline to week 24, the total number of new Gd+ lesions was reduced by 75% and the mean number of new/newly enlarging T2 hyperintense lesions was reduced by 63% (both p < 0.0001). Flushing and flushing-related symptoms, and gastrointestinal events were adverse events related to DMF treatment. Efficacy and safety results in the Japanese subgroup and the East Asian subgroup (which included patients from Japan, Taiwan, and South Korea) were consistent with the overall study population. The strong efficacy and favorable benefit-risk profile of DMF extends to Japanese, and more broadly, East Asian patients with RRMS. This trial is registered on ClinicalTrials.gov (identifier: NCT01838668 ), April 20, 2013 (retrospectively registered). The registration can be found at the following URL: https://clinicaltrials.gov/ct2/show/NCT01838668
- Open Access
- 18 October 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 35314
Altered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy
Multiple sclerosis (MS) is a T cell-mediated autoimmune disease. Fingolimod, a highly effective disease-modifying drug for MS, retains CCR7+ central memory T cells in which autoaggressive T cells putatively exist, in secondary lymphoid organs, although relapse may still occur in some patients. Here, we analyzed the T cell phenotypes of fingolimod-treated, fingolimod-untreated patients, and healthy subjects. The frequency of CD56+ T cells and granzyme B-, perforin-, and Fas ligand-positive T cells significantly increased during fingolimod treatment. Each T cell subpopulation further increased during relapse. Interestingly, T cells from fingolimod-treated patients exhibited interferon-γ biased production, and more myelin basic protein-reactive cells was noted in CD56+ than in CD56− T cells. It is likely that the altered T cell phenotypes play a role in MS relapse in fingolimod-treated patients. Further clinical studies are necessary to investigate whether altered T cell phenotypes are a biomarker for relapse under fingolimod therapy.
- 18 October 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 35314
Open AccessAltered T cell phenotypes associated with clinical relapse of multiple sclerosis patients receiving fingolimod therapy
Multiple sclerosis (MS) is a T cell-mediated autoimmune disease. Fingolimod, a highly effective disease-modifying drug for MS, retains CCR7+ central memory T cells in which autoaggressive T cells putatively exist, in secondary lymphoid organs, although relapse may still occur in some patients. Here, we analyzed the T cell phenotypes of fingolimod-treated, fingolimod-untreated patients, and healthy subjects. The frequency of CD56+ T cells and granzyme B-, perforin-, and Fas ligand-positive T cells significantly increased during fingolimod treatment. Each T cell subpopulation further increased during relapse. Interestingly, T cells from fingolimod-treated patients exhibited interferon-γ biased production, and more myelin basic protein-reactive cells was noted in CD56+ than in CD56− T cells. It is likely that the altered T cell phenotypes play a role in MS relapse in fingolimod-treated patients. Further clinical studies are necessary to investigate whether altered T cell phenotypes are a biomarker for relapse under fingolimod therapy.
- 1 September 2014
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 274 (1-2) , 155-160
Antibodies to neural and non-neural autoantigens in Japanese patients with CNS demyelinating disorders
- 1 September 2014
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 274 (1-2) , 155-160
Antibodies to neural and non-neural autoantigens in Japanese patients with CNS demyelinating disorders